Back to results
US 2017/0253590 A1Published application
Small molecule ire1-alpha inhibitors
AssigneeCornell University
InventorsLaurie H. Glimcher, Sarah Elizabeth Bettigole, Juan Rodrigo Cubillos Ruiz, Joseph P. Vacca
Life of this patent
Estimating the term…
Abstract
Described herein are IRE1α inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application.
Claims40
A compound of formula I,
- wherein:
- A and B are separately each a heterocyclyl ring or a phenyl group, where the A ring has x R1 substituents;
- C is phenyl or pyridinyl;
- D is heterocyclyl ring;
- linkage1 is a single bond between A and B;
- linkage2 is a C1-C3 alkylamido, amidoalkyl, amino, urea, alkylurea, or ureaalkyl with a first and second terminal atom;
- y is an integer of 0-3, and when y is 0, the linkage between the rings is a single bond;
- x is an integer of 0-4;
- v is an integer of 0-2;
- R1 substituents on the A ring are selected from amino, optionally substituted C1-C4 alkyl, optionally substituted ether, optionally substituted C1-C4 alkoxy, oxy, hydroxy, —NH—SO2-phenyl-(R5), and cyano;
- R2 substituents on the B ring are selected from amino, and optionally substituted C1-C4 alkyl;
- R3 substituents on the C ring are selected from halo, CF3, optionally substituted C1-C4 alkyl, and optionally substituted heteroaryl;
- and
- R4 substituents on the D ring are selected from optionally substituted C1-C4 alkyl, optionally substituted C1-C4 alkoxy, (optionally substituted C1-C4 alkylene)-OH, hydroxy, optionally substituted aryl, optionally substituted benzyl, and optionally substituted benzaldehyde;
- and
- R5 is halo;
- or
- a pharmaceutically acceptable salt thereof.
15 more elements
The compound of claim, wherein the A ring is a fusion of two rings.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A compound of formula Ia:
- wherein,
- A1 is N, CH, or CR1;
- A2 is N, CH, or CR1;
- A3 is N, CH, or CR1;
- A4 is N, CH, or CR1;
- A5 is N, CH, or CR1;
- A6 is N, CH, or CR1;
- A7 is N CH, or CR1;
- v is an integer of 0-2;
- each R1 is NH2 or OH;
- provided that the number of R1 on the A ring does not exceed 4;
- B is selected from:
- each R2 is independently selected from H and optionally substituted C1-C4 alkyl;
- X1 and X2 are each independently CH2 or NH;
- with the provision that X1 and X2 are not each CH2,
- R3 is selected from H, halo, CF3, optionally substituted C1-C4 alkyl, and optionally substituted heteroaryl;
- D is a heterocyclyl ring containing at least one N atom;
- and
- each R4 is selected from H, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 alkoxy, (optionally substituted C1-C4 alkylene)-OH, hydroxy, optionally substituted aryl, and optionally substituted benzyl;
- or
- a pharmaceutically acceptable salt thereof.
18 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.